Market Overview

Intercept Pharma Begins Phase 2 NASH Trial of OCA in Japan

Related ICPT
Intercept Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology
The Top 25 Analysts On Wall Street

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that its partner Dainippon Sumitomo Pharma (DSP) has initiated a phase 2 clinical trial of obeticholic acid (OCA) in adult nonalcoholic steatohepatitis (NASH) patients in Japan.

The trial is studying the efficacy and safety of a once daily dose of OCA, with the goal of randomizing 200 NASH patients to receiving OCA or placebo. The primary endpoint will be evaluated by histological improvement. DSP expects to complete the trial in the first half of 2016.

Posted-In: News FDA

 

Related Articles (ICPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters